P
P

Pfizer

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

U.S. STOCKS VBI Vaccine, Precision BioSciences, American Battery Technology

BUZZ-U.S. STOCKS ON THE MOVE-VBI Vaccine, Precision BioSciences, American Battery Technology Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures rebounded on Wednesday as easing Treasury yields boosted megacaps, while investors awaited developments on a U.S.
C
C
P
T
U

FDA Approves Bosutinib For Pediatric Patients With Chronic Myelogenous Leukemia

BRIEF-FDA Approves Bosutinib For Pediatric Patients With Chronic Myelogenous Leukemia Sept 27 (Reuters) - Pfizer Inc PFE.N : FDA: APPROVES BOSUTINIB FOR PEDIATRIC PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA FDA: ALSO APPROVED A NEW CAPSULE DOSAGE FORM OF BOSUTINIB AVAILABLE IN STRENGTHS OF 50 MG AND 100 MG Further company coverage: PFE.N
P

Pharma lobby says EU ban on 'forever chemicals' would halt drug production

Pharma lobby says EU ban on 'forever chemicals' would halt drug production By Ludwig Burger FRANKFURT, Sept 27 (Reuters) - European drugmakers warned that a proposed complete ban on substances known as PFAS or " forever chemicals " would render medicine production in the region impossible, part of a high-stakes wrangle between manufacturers and environmental regulators.
B
N
P

U.S. STOCKS New Oriental Education, Ginkgo Bioworks

BUZZ-U.S. STOCKS ON THE MOVE-New Oriental Education, Ginkgo Bioworks Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures rebounded on Wednesday as retreating Treasury yields boosted megacaps, while investors awaited developments on a U.S.
C
C
P
U

Ginkgo Bioworks jumps on drug development tie-up with Pfizer

BUZZ-Ginkgo Bioworks jumps on drug development tie-up with Pfizer ** Biotech company Ginkgo Bioworks DNA.N rises 15.6% to $2 premarket after signing a drug development partnership deal with Pfizer PFE.N for up to $331 million ** As part of the deal, Pfizer will use Ginkgo's RNA technology to advance the discovery and development of therapeutics - D
P

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.